Chargement en cours...
Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) has been a model disease in the development of targeted therapies. After nearly 40 years of the recognition of the chromosomal abnormality that defines CML, specific therapy was developed, initially with imatinib mesylate, which has transformed our treatment algorithms...
Enregistré dans:
| Publié dans: | J Clin Oncol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Clinical Oncology
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4979134/ https://ncbi.nlm.nih.gov/pubmed/21220597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.3619 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|